bipolar therapy prostate cancer; bloodmarkers/ar

Samuel Denmeade, MD, of Johns Hopkins University School of Medicine, highlights his research on blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial. This research was presented as a late-breaking abstract at the 2024...